Dr. Meredith A McKean
Claim this profileSarah Cannon Research Institute
Expert in Solid Tumors
Expert in Tumors
34 reported clinical trials
66 drugs studied
Area of expertise
1Solid Tumors
Global LeaderStage IV
Stage III
TSC1 positive
2Tumors
Global LeaderStage IV
Stage III
TSC1 positive
Affiliated Hospitals
Clinical Trials Meredith A McKean is currently running
NM6603
for Cancer
This study is to assess the MTD and RP2D of NM6603 in adult patients with advanced solid tumors.
Recruiting1 award Phase 112 criteria
TAB004 + Toripalimab
for Solid Cancers
The primary objective is to assess the safety and tolerability of TAB004 as monotherapy and in combination with toripalimab in subjects with selected advanced solid malignancies, including lymphoma, and to evaluate the recommended Phase 2 dose. The secondary objectives are to: 1) describe the pharmacokinetic (PK) profile of TAB004 monotherapy and in combination with toripalimab and to describe the PK profile of toripalimab when administered with TAB004, 2) evaluate antitumor activity of TAB004 monotherapy and in combination with toripalimab; and 3) determine the immunogenicity of TAB004 monotherapy and in combination with toripalimab and to determine the immunogenicity of toripalimab when administered with TAB004. The exploratory objectives are to: 1) evaluate pharmacodynamic effects of TAB004 on its target receptor BTLA, as well as effects on the immune system; 2) evaluate biomarkers that may correlate with activity of TAB004 as monotherapy and in combination with toripalimab; 3) evaluate the utility of BTLA ligand, herpesvirus-entry mediator (HVEM), and additional exploratory biomarkers that could aid in selection of appropriate subjects for TAB004 monotherapy and in combination with toripalimab.
Recruiting1 award Phase 110 criteria
More about Meredith A McKean
Clinical Trial Related1 year of experience running clinical trials · Led 34 trials as a Principal Investigator · 15 Active Clinical TrialsTreatments Meredith A McKean has experience with
- Pembrolizumab
- Nivolumab
- Carboplatin
- ELU001
- SEA-CD40
- Pemetrexed
Breakdown of trials Meredith A McKean has run
Cancer
Melanoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Meredith A McKean specialize in?
Meredith A McKean focuses on Solid Tumors and Tumors. In particular, much of their work with Solid Tumors has involved Stage IV patients, or patients who are Stage III.
Is Meredith A McKean currently recruiting for clinical trials?
Yes, Meredith A McKean is currently recruiting for 14 clinical trials in Nashville Tennessee. If you're interested in participating, you should apply.
Are there any treatments that Meredith A McKean has studied deeply?
Yes, Meredith A McKean has studied treatments such as Pembrolizumab, Nivolumab, Carboplatin.
What is the best way to schedule an appointment with Meredith A McKean?
Apply for one of the trials that Meredith A McKean is conducting.
What is the office address of Meredith A McKean?
The office of Meredith A McKean is located at: Sarah Cannon Research Institute, Nashville, Tennessee 37205 United States. This is the address for their practice at the Sarah Cannon Research Institute.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.